NCT04129502

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

CompletedPHASE3INTERVENTIONAL

Trial Details

Start: 2020-01-10Est. Completion: 2026-09-22

Enrollment target: 354 participants

Locations

City of Hope National Medical Center, Long Beach, California, United States
University of California Irvine, Orange, California, United States
Stanford University, Palo Alto, California, United States
AdventHealth, Orlando, Florida, United States
Northwestern University, Chicago, Illinois, United States
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
Beth Israel Deaconess Medical Center - 330 Brookline Ave, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Sarah Cannon Cancer Center, Nashville, Tennessee, United States
University of Virginia Health System, Charlottesville, Virginia, United States
GenesisCare North Shore, St Leonards, New South Wales, Australia
Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
Flinders Medical Centre, Bedford Park, South Australia, Australia
Klinik Floridsdorf, Vienna, Austria
Cliniques Universitaires Saint-Luc, Brussels, Brussels Capital, Belgium

Non-small Cell Lung Cancer

This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participa…

Bakersfield, United StatesEst. completion Jan 24, 2028

Non-small Cell Lung Cancer

Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non…

Birmingham, United StatesEst. completion Dec 7, 2029

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.